JP2014506321A5 - - Google Patents

Download PDF

Info

Publication number: JP2014506321A5
Authority: JP; Japan
Prior art keywords: certain embodiments; patient; corticosteroid; registered trademark; asthma
Prior art date: 2011-12-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2013544814A

Other languages

English (en)

Japanese (ja)

Other versions

JP6005657B2 (ja

JP2014506321A (ja

Filing date

2011-12-16

Publication date

2015-01-22

2011-12-16 Application filed filed Critical

2011-12-16 Priority claimed from PCT/US2011/065410 external-priority patent/WO2012083132A2/en

2014-03-13 Publication of JP2014506321A publication Critical patent/JP2014506321A/ja

2015-01-22 Publication of JP2014506321A5 publication Critical patent/JP2014506321A5/ja

2016-10-12 Application granted granted Critical

2016-10-12 Publication of JP6005657B2 publication Critical patent/JP6005657B2/ja

Status Active legal-status Critical Current

2031-12-16 Anticipated expiration legal-status Critical

Links

239000003246 corticosteroid Substances 0.000 description 16
229940125386 long-acting bronchodilator Drugs 0.000 description 14
208000006673 asthma Diseases 0.000 description 12
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 8
208000023504 respiratory system disease Diseases 0.000 description 8
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 7
239000003199 leukotriene receptor blocking agent Substances 0.000 description 7
229940124624 oral corticosteroid Drugs 0.000 description 7
PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 6
229940035073 symbicort Drugs 0.000 description 6
229960001334 corticosteroids Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 4
229960000278 theophylline Drugs 0.000 description 4
FCSXYHUNDAXDRH-OKMNHOJOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 FCSXYHUNDAXDRH-OKMNHOJOSA-N 0.000 description 3
RATSWNOMCHFQGJ-XODSYJLDSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-XODSYJLDSA-N 0.000 description 3
229940031472 brovana Drugs 0.000 description 3
229940085861 flovent Drugs 0.000 description 3
229940127212 long-acting beta 2 agonist Drugs 0.000 description 3
229940100119 perforomist Drugs 0.000 description 3
229960000289 fluticasone propionate Drugs 0.000 description 2
229940125369 inhaled corticosteroids Drugs 0.000 description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
229940072266 pulmicort Drugs 0.000 description 1

JP2013544814A 2010-12-16 2011-12-16 Ｔｈ２阻害に関連する診断及び治療 Active JP6005657B2 (ja)

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US45976010P	2010-12-16	2010-12-16
US61/459,760		2010-12-16
US201161465425P	2011-03-18	2011-03-18
US61/465,425		2011-03-18
US201161484650P	2011-05-10	2011-05-10
US61/484,650		2011-05-10
US201161574485P	2011-08-02	2011-08-02
US61/574,485		2011-08-02
US201161557295P	2011-11-08	2011-11-08
US61/557,295		2011-11-08
PCT/US2011/065410 WO2012083132A2 (en)	2010-12-16	2011-12-16	Diagnosis and treatments relating to th2 inhibition

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2014237322A Division JP6502069B2 (ja)	2010-12-16	2014-11-25	Ｔｈ２阻害に関連する診断及び治療
JP2015160118A Division JP6297526B2 (ja)	2010-12-16	2015-08-14	Ｔｈ２阻害に関連する診断及び治療

Publications (3)

Publication Number	Publication Date
JP2014506321A JP2014506321A (ja)	2014-03-13
JP2014506321A5 true JP2014506321A5 (2)	2015-01-22
JP6005657B2 JP6005657B2 (ja)	2016-10-12

Family

ID=46234723

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
JP2013544814A Active JP6005657B2 (ja)	2010-12-16	2011-12-16	Ｔｈ２阻害に関連する診断及び治療
JP2014237322A Active JP6502069B2 (ja)	2010-12-16	2014-11-25	Ｔｈ２阻害に関連する診断及び治療
JP2015160118A Active JP6297526B2 (ja)	2010-12-16	2015-08-14	Ｔｈ２阻害に関連する診断及び治療
JP2017156349A Pending JP2018009998A (ja)	2010-12-16	2017-08-14	Ｔｈ２阻害に関連する診断及び治療

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
JP2014237322A Active JP6502069B2 (ja)	2010-12-16	2014-11-25	Ｔｈ２阻害に関連する診断及び治療
JP2015160118A Active JP6297526B2 (ja)	2010-12-16	2015-08-14	Ｔｈ２阻害に関連する診断及び治療
JP2017156349A Pending JP2018009998A (ja)	2010-12-16	2017-08-14	Ｔｈ２阻害に関連する診断及び治療

Country Status (19)

Country	Link
US (4)	US20120156194A1 (2)
EP (2)	EP2652498B1 (2)
JP (4)	JP6005657B2 (2)
KR (4)	KR101616260B1 (2)
CN (4)	CN112168962A (2)
AR (1)	AR084342A1 (2)
AU (1)	AU2011343570B2 (2)
BR (2)	BR122020012255B1 (2)
CA (2)	CA3040095C (2)
HK (1)	HK1215857A1 (2)
IL (2)	IL226821B (2)
MX (2)	MX352789B (2)
MY (1)	MY188365A (2)
NZ (2)	NZ609493A (2)
RU (2)	RU2578468C2 (2)
SG (3)	SG190885A1 (2)
TW (4)	TW201732294A (2)
WO (1)	WO2012083132A2 (2)
ZA (1)	ZA201302979B (2)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3718564T3 (pl)	2003-12-23	2024-03-18	Genentech, Inc.	Nowe przeciwciała anty-IL 13 i ich zastosowania
BRPI0906261A2 (pt) *	2008-03-31	2015-07-07	Genentech Inc	"métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
RU2578468C2 (ru)	2010-12-16	2016-03-27	Дженентек, Инк.	Способы диагностики и лечения, связанные с ингибированием th2
CN107099581B (zh) *	2012-03-27	2021-07-13	弗·哈夫曼-拉罗切有限公司	预测、诊断和治疗特发性肺纤维化的方法
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2
WO2014151648A1 (en) *	2013-03-15	2014-09-25	Coronado Biosciences, Inc.	Treatment of autoimmune disease using helminthic parasites
KR20150131177A (ko)	2013-03-15	2015-11-24	제넨테크, 인크.	항-CRTh2 항체 및 그의 용도
AU2014306956B2 (en)	2013-08-12	2019-11-21	Astrazeneca Ab	Methods for reducing exacerbation rates of asthma using benralizumab
SMT202100152T1 (it) *	2013-08-12	2021-05-07	Astrazeneca Ab	Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
RU2728578C2 (ru)	2013-08-12	2020-07-30	Астразенека Аб	Способы нормализации симптомов астмы с применением бенрализумаба
RU2016107435A (ru)	2013-09-13	2017-10-18	Дженентек, Инк.	Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh)	2013-09-13	2025-11-07	豪夫迈·罗氏有限公司	包含纯化的重组多肽的方法和组合物
US10553320B1 (en) *	2013-09-19	2020-02-04	Cerner Innovation, Inc.	Personal analysis and chronotherapy
JP6250351B2 (ja) *	2013-09-30	2017-12-20	シスメックス株式会社	好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
WO2015057668A1 (en) *	2013-10-15	2015-04-23	Medimmune, Llc	Methods for treating chronic obstructive pulmonary disease using benralizumab
AR098155A1 (es) *	2013-10-23	2016-05-04	Genentech Inc	Métodos para diagnosticar y tratar trastornos eosinofílicos
ES2866935T3 (es)	2014-01-10	2021-10-20	Anaptysbio Inc	Anticuerpos dirigidos contra interleucina-33 (IL-33)
CA2937387A1 (en)	2014-01-27	2015-07-30	Medimmune, Llc	Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
HK1232290A1 (zh)	2014-02-07	2018-01-05	Medimmune, Llc	检测人类骨膜蛋白的新型测定
WO2015126750A1 (en) *	2014-02-19	2015-08-27	Array Biopharma Inc.	BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO TREATMENT WITH A CRTh2 INHIBITOR
UA117608C2 (uk) *	2014-02-21	2018-08-27	Дженентек, Інк.	Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
CA2943326A1 (en)	2014-04-11	2015-10-15	Novartis Ag	Methods of selectively treating asthma using il-13 antagonists
MA40164A (fr) *	2014-06-27	2017-05-03	Sanofi Sa	Anticorps bispécifiques anti-il4-il13
TW201628647A (zh)	2014-06-27	2016-08-16	賽諾菲公司	抗－ｉｌ４－ｉｌ１３雙特異性抗體
UA122670C2 (uk) *	2014-09-08	2020-12-28	Сефалон, Інк.	Спосіб лікування еозинофільної астми у пацієнта
EP3194446B1 (en) *	2014-09-18	2022-10-26	Cedars-Sinai Medical Center	Compositions and methods for treating fibrosis
JP7231326B2 (ja) *	2014-11-10	2023-03-01	ジェネンテック，インコーポレイテッド	Ｉｌ－３３媒介性障害のための治療及び診断方法
CR20170240A (es)	2014-11-10	2018-04-03	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos
KR20170094165A (ko)	2014-12-23	2017-08-17	제넨테크, 인크.	화학요법-내성 암을 치료 및 진단하는 조성물 및 방법
AU2016205188A1 (en)	2015-01-09	2017-06-22	Medimmune, Llc	Assay to detect human DPP-4
MX2017011486A (es) *	2015-03-16	2018-06-15	Genentech Inc	Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
EP3371225A2 (en)	2015-11-04	2018-09-12	AstraZeneca AB	Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
EP3417079A4 (en) *	2016-02-17	2019-07-10	Icahn School of Medicine at Mount Sinai	NASAL BIOMARKERS FOR ASTHMA
MX2018013038A (es)	2016-04-27	2019-03-28	Pfizer	Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
JP6871948B2 (ja)	2016-04-27	2021-05-19	アッヴィ・インコーポレイテッド	抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
PT3528838T (pt) *	2016-09-23	2023-09-04	Hoffmann La Roche	Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
JP6995127B2 (ja)	2017-02-10	2022-02-04	ジェネンテック，インコーポレイテッド	抗トリプターゼ抗体、その組成物、及びその使用
KR20220098056A (ko)	2018-02-09	2022-07-08	제넨테크, 인크.	비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
WO2019183131A1 (en) *	2018-03-19	2019-09-26	Bioventures, Llc	Periostin antibodies and methods of using the same
CN108977511A (zh) *	2018-07-03	2018-12-11	张罗	检测鼻腔脱落细胞中cst1基因表达量的方法及应用
CN111415728A (zh) *	2019-11-25	2020-07-14	刘雷	基于cnn和gan的ct图像数据自动分类方法及设备
PE20230252A1 (es)	2020-03-13	2023-02-07	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos de estos
CN113501878B (zh) *	2021-02-03	2022-12-02	北京智仁美博生物科技有限公司	针对人tslp的多种抗体及其用途
TWI859566B (zh) *	2021-08-13	2024-10-21	美商德米拉股份有限公司	用於治療異位性皮膚炎之il-13抗體
JP7805983B2 (ja)	2022-03-22	2026-01-26	アッヴィ・インコーポレイテッド	ブルトン型チロシンキナーゼを分解するためのピリミジン
EP4540284A2 (en) *	2022-06-17	2025-04-23	Apogee Therapeutics, Inc.	Antibodies that bind interleukin 13 and methods of use

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4578349A (en)	1982-04-08	1986-03-25	Abbott Laboratories	Immunoassay for carcinoembryonic antigen (CEA)
US4818709A (en)	1983-01-21	1989-04-04	Primus Frederick J	CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5122599A (en)	1986-08-13	1992-06-16	Molecular Diagnostics, Inc.	CDNAS coding for members of the carcinoembryonic antigen family
US6022958A (en)	1986-08-13	2000-02-08	Bayer Corporation	cDNAs coding for members of the carcinoembryonic antigen family
US5231009A (en)	1986-08-13	1993-07-27	Molecular Diagnostics, Inc.	Cdnas coding for members of the carcinoembryonic antigen family
US5274087A (en)	1986-08-13	1993-12-28	Molecular Diagnostics, Inc.	cDNA coding for carcinoembryonic antigen (CEA)
EP0263933B1 (en)	1986-08-13	1993-10-20	Miles Inc.	A cDNA coding for carcinoembryonic antigen
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja)	1987-03-18	2000-10-23	エス・ビィ・２・インコーポレイテッド	変性抗体の、または変性抗体に関する改良
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
GB8800078D0 (en)	1988-01-05	1988-02-10	Ciba Geigy Ag	Novel antibodies
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en)	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
US7018809B1 (en)	1991-09-19	2006-03-28	Genentech, Inc.	Expression of functional antibody fragments
FI941572A7 (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en)	1992-02-06	1993-08-19	L.L. Houston	Biosynthetic binding protein for cancer marker
JPH05268982A (ja)	1992-03-27	1993-10-19	Hoechst Japan Ltd	骨形成作用を有する新規な蛋白質およびその製造法
US5596072A (en)	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
WO1994004680A1 (en)	1992-08-21	1994-03-03	Schering Corporation	Human interleukin-13
DK0752248T3 (da)	1992-11-13	2000-11-13	Idec Pharma Corp	Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
WO1995011923A1 (en)	1993-10-29	1995-05-04	Dana-Farber Cancer Institute, Inc.	A novel tumor marker and novel method of isolating same
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
DE69535316T2 (de)	1994-10-05	2007-05-31	Immunex Corp., Seattle	Als lerk6 bezeichnetes cytokin
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6518061B1 (en)	1995-03-15	2003-02-11	The United States Of America As Represented By The Department Of Health And Human Services	IL-13 receptor specific chimeric proteins and uses thereof
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6911530B1 (en)	1995-10-23	2005-06-28	Amrad Operations, Pty., Ltd.	Haemopoietin receptor and genetic sequences encoding same
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
DE19614062A1 (de)	1996-04-09	1997-10-16	Bayer Ag	Verfahren zur kontinuierlichen Herstellung von Diarylcarbonaten
US20060073133A1 (en) *	1997-04-02	2006-04-06	Kikly Kristine K	Sialoadhesin factor-3 antibodies
EP1017807A1 (en)	1997-05-29	2000-07-12	Board Of Regents The University Of Texas System	Osf2/cbfa1 compositions and methods of use
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
ES2244066T3 (es)	1997-06-24	2005-12-01	Genentech, Inc.	Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1000084A4 (en)	1997-07-08	2003-03-26	Human Genome Sciences Inc	123 HUMAN SECRETED PROTEINS
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
AU759779B2 (en)	1997-10-31	2003-05-01	Genentech Inc.	Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
DK1034298T3 (da)	1997-12-05	2012-01-30	Scripps Research Inst	Humanisering af murint antistof
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ATE375365T1 (de)	1998-04-02	2007-10-15	Genentech Inc	Antikörper varianten und fragmente davon
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6482403B1 (en)	1998-05-29	2002-11-19	Heska Corporation	Caniney IL-13 immunoregulatory proteins and uses thereof
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
PL209392B1 (pl)	1999-01-15	2011-08-31	Genentech Inc	Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
WO2000044407A2 (en)	1999-02-01	2000-08-03	Amgen Canada	Materials and methods to inhibit hodgkin and reed sternberg cell growth
CA2704600C (en)	1999-04-09	2016-10-25	Kyowa Kirin Co., Ltd.	A method for producing antibodies with increased adcc activity
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
ES2248127T3 (es)	1999-10-04	2006-03-16	Medicago Inc.	Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PREPARING A POLYPEPTIDE
EP1240319A1 (en)	1999-12-15	2002-09-18	Genentech, Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU767394C (en)	1999-12-29	2005-04-21	Immunogen, Inc.	Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ATE402192T1 (de)	2000-03-03	2008-08-15	Kyowa Hakko Kogyo Kk	Anti-ccr4 antikörper und fragmente davon
US7439064B2 (en)	2000-03-09	2008-10-21	Wicell Research Institute, Inc.	Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
JP2003531588A (ja)	2000-04-11	2003-10-28	ジェネンテック・インコーポレーテッド	多価抗体とその用途
KR20030069989A (ko)	2000-09-08	2003-08-27	다이이찌 산토리 파마 가부시키가이샤	심부전 치료제
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en)	2000-10-06	2002-04-18	Kyowa Hakko Kirin Co., Ltd.	Antibody composition-producing cell
AU1091802A (en)	2000-10-20	2002-04-29	Chugai Pharmaceutical Co Ltd	Degraded agonist antibody
EP1333850B1 (en)	2000-10-20	2008-08-20	Genetics Institute, Inc.	Use of il-13 inhibitors for the treatment of tumors
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
JP4155561B2 (ja) *	2000-12-26	2008-09-24	国立大学法人佐賀大学	アレルギー性疾患検査方法
US6596240B2 (en)	2001-01-12	2003-07-22	Porex Corporation	Pipette tip for easy mounting and ejecting from a pipette
PT2000545E (pt)	2001-06-20	2011-12-21	Genentech Inc	Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
US20050107595A1 (en)	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
NZ571596A (en)	2001-08-03	2010-11-26	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003016471A2 (en)	2001-08-13	2003-02-27	Dana-Farber Cancer Institute, Inc.	Periostin-based diagnostic assays
CA2458627C (en)	2001-08-31	2013-09-10	Kyowa Kirin Co., Ltd.	Human cdr-grafted antibody and antibody fragment thereof
US7384736B2 (en)	2001-09-06	2008-06-10	Decode Genetics Ehf.	Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
GB0123951D0 (en) *	2001-10-05	2001-11-28	Glaxo Group Ltd	Therapies for treating respiratory diseases
CA2463879C (en)	2001-10-25	2012-12-04	Genentech, Inc.	Glycoprotein compositions
CA2464695A1 (en)	2001-10-26	2003-05-01	Centocor, Inc.	Il-13 mutein proteins, antibodies, compositions, methods and uses
WO2003072827A1 (en)	2001-10-31	2003-09-04	Children's Hospital Medical Center	Method for diagnosis and treatment of rheumatoid arthritis
WO2003038055A2 (en)	2001-10-31	2003-05-08	Mds Proteomics, Inc.	Proteins involved in regulation of adipocytes and uses related thereto
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
AU2003223497A1 (en)	2002-04-05	2003-10-27	Centocor, Inc.	Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
DE20205500U1 (de)	2002-04-09	2002-07-11	Hurth, Ursula, 66450 Bexbach	Tampon
EP1500400A4 (en)	2002-04-09	2006-10-11	Kyowa Hakko Kogyo Kk	MEDICAMENT WITH ANTIBODY COMPOSITION
EP1498490A4 (en)	2002-04-09	2006-11-29	Kyowa Hakko Kogyo Kk	PROCESS FOR PREPARING ANTIBODY COMPOSITION
BR0309145A (pt)	2002-04-09	2005-02-01	Kyowa Hakko Kogyo Kk	Células das quais o genoma é modificado
CA2481925A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Therapeutic agent for patients having human fc.gamma.riiia
CA2481658A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to fcy receptor iiia
ATE503829T1 (de)	2002-04-09	2011-04-15	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
WO2003086458A1 (en)	2002-04-12	2003-10-23	Medimmune, Inc.	Recombinant anti-interleukin-9 antibodies
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
SE522615C2 (sv)	2002-07-09	2004-02-24	Martin Tiberg Med Tiberg Techn	En metod och ett system för biometrisk identifiering eller verifiering.
JP2004121218A (ja)	2002-08-06	2004-04-22	Jenokkusu Soyaku Kenkyusho:Kk	気管支喘息または慢性閉塞性肺疾患の検査方法
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en)	2002-12-16	2011-01-11	Genentech Inc	Immunoglobulin variants and uses thereof
WO2004065416A2 (en)	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
DE10304350B3 (de)	2003-02-03	2004-06-09	Sabeu Kunststoffwerk Northeim Gmbh	Behälterverschluß
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004229501B2 (en)	2003-04-11	2011-08-18	Medimmune, Llc	Recombinant IL-9 antibodies and uses thereof
US8394379B2 (en) *	2003-05-15	2013-03-12	Iogenetics, Llc	Targeted cryptosporidium biocides
EP1628679A2 (en)	2003-05-23	2006-03-01	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumors of glial origin
WO2004106495A2 (en)	2003-05-29	2004-12-09	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP2327795B1 (en)	2003-06-10	2017-08-09	The Trustees Of Boston University	Detection methods for disorders of the lung
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
WO2005019471A2 (en)	2003-08-13	2005-03-03	Temple University Of The Commonwealth System Of Higher Education	Periostin-like factor: compositions and methods for making and using the same
US20050053549A1 (en) *	2003-09-10	2005-03-10	Aperon Biosystems Corp.	Method for treating airway disorders
JPWO2005035586A1 (ja)	2003-10-08	2007-11-22	協和醗酵工業株式会社	融合蛋白質組成物
JPWO2005035778A1 (ja)	2003-10-09	2006-12-21	協和醗酵工業株式会社	α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
US9296820B2 (en)	2003-11-05	2016-03-29	Roche Glycart Ag	Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en)	2003-11-06	2016-08-31	Seattle Genetics, Inc.	Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005053742A1 (ja)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	抗体組成物を含有する医薬
PL3718564T3 (pl) *	2003-12-23	2024-03-18	Genentech, Inc.	Nowe przeciwciała anty-IL 13 i ich zastosowania
EP1740615B1 (en)	2004-03-31	2014-11-05	Genentech, Inc.	Humanized anti-tgf-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
PT1737891E (pt)	2004-04-13	2013-04-16	Hoffmann La Roche	Anticorpos anti p-selectina
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20070048785A1 (en)	2004-06-09	2007-03-01	Lin Laura L	Anti-IL-13 antibodies and complexes
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
DK1791565T3 (en)	2004-09-23	2016-08-01	Genentech Inc	Cysteingensplejsede antibodies and conjugates
KR100635540B1 (ko)	2004-10-12	2006-10-18	경북대학교 산학협력단	신규한 염증성 질환의 예방 또는 치료용 약학적 조성물
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
EP1824886B1 (en) *	2004-11-17	2010-12-22	Amgen Inc.	Fully human monoclonal antibodies to il-13
AU2006296399B2 (en)	2005-09-30	2011-01-20	Medimmune Limited	Interleukin-13 antibody composition
WO2007045477A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Human antibodies against il-13 and therapeutic uses
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en)	2005-12-02	2008-10-01	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
WO2007077934A1 (ja)	2005-12-28	2007-07-12	Asubio Pharma Co., Ltd.	抗ペリオスチン抗体およびそれを含有するペリオスチンが関与する疾患の予防または治療用医薬組成物
US8017119B2 (en) *	2005-12-28	2011-09-13	Daiichi Sankyo Company, Ltd.	Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
JP2009525267A (ja)	2006-01-11	2009-07-09	アエロヴァンスインコーポレイティッド	ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
GB0600488D0 (en)	2006-01-11	2006-02-22	Glaxo Group Ltd	Immunoglobulins
EP1987359B1 (en) *	2006-02-22	2015-03-18	Philogen S.p.A.	Vascular tumor markers
TW200812616A (en)	2006-05-09	2008-03-16	Genentech Inc	Binding polypeptides with optimized scaffolds
US20070275925A1 (en)	2006-05-17	2007-11-29	Regents Of The University Of California	Asthma diagnosis and therapy
EP2052088A2 (en)	2006-08-02	2009-04-29	Genizon Biosciences	Genemap of the human genes associated with psoriasis
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
JP2010502224A (ja)	2006-09-08	2010-01-28	アボット・ラボラトリーズ	インターロイキン１３結合タンパク質
JP5919593B2 (ja) *	2006-10-11	2016-05-18	フージョンアンティボディーズリミテッド	併用療法
JP4369468B2 (ja)	2006-12-15	2009-11-18	日本分光株式会社	不可逆反応測定方法
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CA2674608A1 (en)	2007-01-09	2008-07-17	Wyeth	Anti-il-13 antibody formulations and uses thereof
SI2132230T1 (sl)	2007-03-22	2014-07-31	Genentech, Inc.	Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
AR066240A1 (es) *	2007-04-23	2009-08-05	Wyeth Corp	Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
DK2152290T3 (da)	2007-04-30	2014-08-18	Glaxosmithkline Llc	Fremgangsmåder til indgivelse af anti-il-5-antistoffer
WO2008140455A1 (en)	2007-05-15	2008-11-20	Tanox, Inc.	Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
KR101560843B1 (ko)	2007-06-27	2015-10-15	고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸	페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
KR20100047866A (ko)	2007-07-11	2010-05-10	애로반스, 인코포레이티드	약제학적 폴리펩타이드 건조 분말 에어로졸 제형 및 이의 제조 방법
JP6157046B2 (ja)	2008-01-07	2017-07-05	アムジェンインコーポレイテッド	静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
BRPI0906261A2 (pt) *	2008-03-31	2015-07-07	Genentech Inc	"métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
US8420310B2 (en)	2008-06-05	2013-04-16	Saga University	Method for detection of idiopathic interstitial pneumonia
WO2010007701A1 (ja)	2008-07-18	2010-01-21	国立大学法人東京工業大学	心筋壊死を伴う疾患の治療薬及び検査薬
EP2329025A4 (en) *	2008-09-08	2012-04-25	Ottawa Hospital Res Inst	PERIOSTIN-INDUCED PANCAKE RENEWAL
JP5522717B2 (ja) *	2008-09-19	2014-06-18	国立大学法人佐賀大学	アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法
US20100082438A1 (en) *	2008-10-01	2010-04-01	Ronnie Jack Garmon	Methods and systems for customer performance scoring
FR2944448B1 (fr)	2008-12-23	2012-01-13	Adocia	Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
FR2946349B1 (fr) *	2009-06-03	2013-10-04	Synarc Sas	Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine
RU2578468C2 (ru)	2010-12-16	2016-03-27	Дженентек, Инк.	Способы диагностики и лечения, связанные с ингибированием th2
JP6183809B2 (ja)	2011-09-06	2017-08-23	株式会社シノテスト	ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法

2011
- 2011-12-16 RU RU2013132733/15A patent/RU2578468C2/ru active
- 2011-12-16 TW TW106106464A patent/TW201732294A/zh unknown
- 2011-12-16 KR KR1020147035863A patent/KR101616260B1/ko active Active
- 2011-12-16 US US13/328,830 patent/US20120156194A1/en not_active Abandoned
- 2011-12-16 TW TW108100885A patent/TWI708944B/zh active
- 2011-12-16 SG SG2013040431A patent/SG190885A1/en unknown
- 2011-12-16 KR KR1020137013288A patent/KR101615420B1/ko active Active
- 2011-12-16 JP JP2013544814A patent/JP6005657B2/ja active Active
- 2011-12-16 NZ NZ609493A patent/NZ609493A/en unknown
- 2011-12-16 BR BR122020012255-2A patent/BR122020012255B1/pt active IP Right Grant
- 2011-12-16 MX MX2013006712A patent/MX352789B/es active IP Right Grant
- 2011-12-16 SG SG10201401746TA patent/SG10201401746TA/en unknown
- 2011-12-16 TW TW108127617A patent/TWI732259B/zh active
- 2011-12-16 CN CN202011057363.0A patent/CN112168962A/zh active Pending
- 2011-12-16 AR ARP110104747A patent/AR084342A1/es unknown
- 2011-12-16 MX MX2017015918A patent/MX371228B/es unknown
- 2011-12-16 MY MYPI2013001957A patent/MY188365A/en unknown
- 2011-12-16 SG SG10201401763SA patent/SG10201401763SA/en unknown
- 2011-12-16 AU AU2011343570A patent/AU2011343570B2/en active Active
- 2011-12-16 CN CN201180067674.8A patent/CN103688171B/zh active Active
- 2011-12-16 RU RU2015139698A patent/RU2737245C2/ru active
- 2011-12-16 NZ NZ713202A patent/NZ713202A/en unknown
- 2011-12-16 CN CN201510591057.8A patent/CN105169390A/zh active Pending
- 2011-12-16 KR KR1020147035860A patent/KR101615474B1/ko active Active
- 2011-12-16 TW TW100146961A patent/TWI666447B/zh active
- 2011-12-16 CA CA3040095A patent/CA3040095C/en active Active
- 2011-12-16 CN CN201510591098.7A patent/CN105175542B/zh active Active
- 2011-12-16 EP EP11848523.4A patent/EP2652498B1/en active Active
- 2011-12-16 BR BR112013013460A patent/BR112013013460A8/pt active Search and Examination
- 2011-12-16 KR KR1020167010543A patent/KR101923282B1/ko active Active
- 2011-12-16 WO PCT/US2011/065410 patent/WO2012083132A2/en not_active Ceased
- 2011-12-16 EP EP18166030.9A patent/EP3447491A3/en active Pending
- 2011-12-16 CA CA2817380A patent/CA2817380C/en active Active
2013
- 2013-04-24 ZA ZA2013/02979A patent/ZA201302979B/en unknown
- 2013-06-09 IL IL226821A patent/IL226821B/en active IP Right Grant
- 2013-09-09 US US14/021,698 patent/US9684000B2/en active Active
- 2013-09-09 US US14/021,947 patent/US9995755B2/en active Active
2014
- 2014-11-25 JP JP2014237322A patent/JP6502069B2/ja active Active
2015
- 2015-08-14 JP JP2015160118A patent/JP6297526B2/ja active Active
2016
- 2016-04-05 HK HK16103827.5A patent/HK1215857A1/zh unknown
2017
- 2017-08-14 JP JP2017156349A patent/JP2018009998A/ja active Pending
2018
- 2018-05-29 US US15/992,115 patent/US11226341B2/en active Active
- 2018-10-10 IL IL262278A patent/IL262278B/en active IP Right Grant

Publication	Publication Date	Title
JP2014506321A5 (2)	2015-01-22
JP6434416B2 (ja)	2018-12-05	ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
AU2014348840B2 (en)	2019-06-06	Inhibitors of influenza viruses replication
KR102210209B1 (ko)	2021-02-01	수면 장애의 치료 및 예방
JP2013535437A5 (2)	2014-08-28
JP2011528332A5 (2)	2012-04-12
JP2009533356A5 (2)	2011-04-21
JP2013544887A5 (2)	2015-05-07
JP2017528494A5 (2)	2018-10-25
WO2009044392A3 (en)	2010-03-04	Novel sirna structures
JP2012517987A5 (ja)	2013-04-04	吸入用の医薬組成物のｆｐｄ特性を設定する方法
NZ625592A (en)	2016-09-30	Compositions and methods for the treatment of hepatic diseases and disorders
JP2014503593A5 (2)	2015-03-19
JP2021525729A5 (2)	2022-06-03
JP2009215293A5 (2)	2012-04-12
JP2019505529A5 (2)	2020-03-26
JP2008110970A5 (2)	2010-10-21
WO2004067006A1 (en)	2004-08-12	Combination of a pde iv inhibitor and a tnf-alpha antagonist
JP2017536380A5 (2)	2019-01-24
Walia et al.	2006	Montelukast in pediatric asthma management
JP2010510257A (ja)	2010-04-02	喘息及びアレルギー性鼻炎の治療におけるアルギナーゼ阻害剤の使用
JP2009508822A5 (2)	2009-06-25
JP2010500284A5 (2)	2010-07-22
TWI333857B (en)	2010-12-01	Intranasal pharmaceutical composition for treating non-viral induced airway inflammation or allergic diseases and uses thereof
US11160814B1 (en)	2021-11-02	Methods of treatment for disease from coronavirus exposure